BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 34663432)

  • 21. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
    Syljuåsen RG; Sørensen CS; Hansen LT; Fugger K; Lundin C; Johansson F; Helleday T; Sehested M; Lukas J; Bartek J
    Mol Cell Biol; 2005 May; 25(9):3553-62. PubMed ID: 15831461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
    Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
    Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint.
    Kim JM; Kakusho N; Yamada M; Kanoh Y; Takemoto N; Masai H
    Oncogene; 2008 May; 27(24):3475-82. PubMed ID: 18084324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway.
    Bao J; Yu Y; Chen J; He Y; Chen X; Ren Z; Xue C; Liu L; Hu Q; Li J; Cui G; Sun R
    Cell Death Dis; 2018 Oct; 9(10):1045. PubMed ID: 30315225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.
    Sundararajan V; Tan TZ; Lim D; Peng Y; Wengner AM; Ngoi NYL; Jeyasekharan AD; Tan DSP
    J Pathol; 2023 Feb; 259(2):194-204. PubMed ID: 36373784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
    Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
    Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.
    Gallmeier E; Hermann PC; Mueller MT; Machado JG; Ziesch A; De Toni EN; Palagyi A; Eisen C; Ellwart JW; Rivera J; Rubio-Viqueira B; Hidalgo M; Bunz F; Göke B; Heeschen C
    Stem Cells; 2011 Mar; 29(3):418-29. PubMed ID: 21308861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cdc7-dependent and -independent phosphorylation of Claspin in the induction of the DNA replication checkpoint.
    Rainey MD; Harhen B; Wang GN; Murphy PV; Santocanale C
    Cell Cycle; 2013 May; 12(10):1560-8. PubMed ID: 23598722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
    Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
    Mutat Res; 2023; 827():111834. PubMed ID: 37531716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of ATR-CHK1 signaling by ubiquitination of CLASPIN.
    Zhu X; Zheng XY; Gong P; Xu X
    Biochem Soc Trans; 2022 Oct; 50(5):1471-1480. PubMed ID: 36196914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in
    Erber J; Steiner JD; Isensee J; Lobbes LA; Toschka A; Beleggia F; Schmitt A; Kaiser RWJ; Siedek F; Persigehl T; Hucho T; Reinhardt HC
    Cancer Res; 2019 Oct; 79(19):4855-4868. PubMed ID: 31405847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.
    Beumer JH; Fu KY; Anyang BN; Siegfried JM; Bakkenist CJ
    BMC Cancer; 2015 Oct; 15():649. PubMed ID: 26438152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway.
    Chaudhary P; Sharma R; Sahu M; Vishwanatha JK; Awasthi S; Awasthi YC
    J Biol Chem; 2013 Jul; 288(28):20532-46. PubMed ID: 23733185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.
    Liu K; Graves JD; Lin FT; Lin WC
    J Biol Chem; 2021; 296():100382. PubMed ID: 33556369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of the DNA damage checkpoint using Xenopus egg extracts.
    Willis J; DeStephanis D; Patel Y; Gowda V; Yan S
    J Vis Exp; 2012 Nov; (69):e4449. PubMed ID: 23149695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.